title: Lysophosphatidic acid level and the incidence of silent brain infarction in patients with nonvalvular atrial fibrillation.
abstract: Lysophosphatidic acid (LPA), which is proposed to play an important role in normal physiological situations such as wound healing, vascular tone, vascular integrity and reproduction, may be involved in the etiology of some diseases such as atherosclerosis, cancer, obesity or myocardial infarction. Abnormal findings, including silent brain infarction (SBI), are frequently observed by magnetic resonance imaging (MRI) in patients with nonvalvular atrial fibrillation (NVAF). However, whether there is a relationship between LPA level and the prevalence of SBI has not been extensively studied. In the present study, the association between them was investigated. 235 patients with NVAF, 116 cases of SBI without NVAF and 120 cases of healthy volunteers (control group), who did not receive any antithrombotic therapy, were enrolled in this study. Plasma LPA levels in the NVAF with SBI group were significantly higher than that in the control group (p < 0.01), NVAF without SBI group (p < 0.01) and SBI without NVAF group (p < 0.01). The LPA levels are lower in the control group than in the NVAF without SBI and SBI without NVAF groups (p < 0.01), however, the latter two groups did not significantly differ from each other for LPA levels (p > 0.05) There were significant differences in the positive rate of platelet activation between each of the groups (p < 0.01). The positive rate of platelet activation was significantly higher in the NVAF with SBI group. We suggest that LPA might be a novel marker for estimation of the status of platelet activation and the risk factor for SBI onset in NVAF patients. We expected that plasma LPA levels could predict the occurrence of SBI in NVAF patients.
authors.affiliation: Department of Neurology, Wendeng Center Hospital of Weihai, the Affiliated Hospital of Weifang Medical College, Weihai, Shandong 264400, China; E-Mails: lzg6598@163169.net (Z.-G.L.); wdchywk@163.com (Z.-C.Y.); jwpz67@126.com (W.-P.J.); zhenwd17@126.com (D.-Z.W.); wdzhx686@sina.com (X.Z.); wxj7979@163.com (X.-J.W.); drlizhou2009@126.com (L.Z.).
authors.forename: Zhen-Guang
authors.initials: ZG
authors.lastname: Li
authors.forename: Zhan-Cai
authors.initials: ZC
authors.lastname: Yu
authors.forename: Yong-Peng
authors.initials: YP
authors.lastname: Yu
authors.forename: Wei-Ping
authors.initials: WP
authors.lastname: Ju
authors.forename: Dao-Zhen
authors.initials: DZ
authors.lastname: Wang
authors.forename: Xia
authors.initials: X
authors.lastname: Zhan
authors.forename: Xi-Juan
authors.initials: XJ
authors.lastname: Wu
authors.forename: Li
authors.initials: L
authors.lastname: Zhou
mesh_terms: D000368:Aged; D001281:Atrial Fibrillation / Q000097:blood* / Q000150:complications / Q000175:diagnosis; D015415:Biomarkers / Q000097:blood; D020520:Brain Infarction / Q000097:blood / Q000150:complications / Q000175:diagnosis*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D015994:Incidence; D008246:Lysophospholipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D015539:Platelet Activation
chemical_list: D015415:Biomarkers; D008246:Lysophospholipids; C032881:lysophosphatidic acid